ARTICLE | Company News
Adipogen Pharma, ChemGenex Pharmaceuticals cancer, metabolic news
November 5, 2007 8:00 AM UTC
CXS will spin out its metabolic disease unit, Autogen Research Pty. Ltd., which will merge with Adipogen and be renamed Verva Pharmaceuticals Ltd. CXS will focus on its cancer portfolio, including Ceflatonin homoharringtonine, a plant alkaloid extracted from Cephalotaxus that is in a Phase II/III trial to treat Gleevec-resistant chronic myelogenous leukemia (CML). ...